Astellas, Indian Generic Cos. Settle IP Fight Over Bladder Drug

Law360 (May 7, 2020, 9:10 PM EDT) -- Astellas Pharma Inc. has recently reached settlements with a pair of Indian drugmakers that are aiming to make generic versions of its patent-protected overactive bladder treatment Myrbetriq.

Citing the settlements, U.S. District Judge Joseph F. Bataillon agreed to dismiss the infringement suit in Delaware federal court against Windlas Healthcare Pvt. Ltd. on Thursday and the suit against Lupin Ltd. on April 29.

The stipulations provided to the court requested claims and counterclaims be dismissed without prejudice but didn't outline further terms. Counsel for the parties didn't immediately respond to requests for comment or details of the settlements late Thursday.

According to...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!